Cingulate enters $25M equity purchase agreement with Lincoln Park Capital

Cingulate Inc.

Lincoln Park Capital commits to buy up to $25M of Cingulate common stock over 36 months, starting after SEC registration effective.
Cingulate issued 120,424 commitment shares to Lincoln Park on July 21, 2025 as consideration for the commitment.
Sales are at Cingulate's discretion with a single-day cap of $150K (up to $500K depending on price) and an Exchange Cap of 1,004,660 shares (19.99% of outstanding).
Proceeds intended for regulatory approval and development of CTx-1301, plus working capital and R&D.
Lincoln Park is barred from short sales or hedging during the term; Cingulate may terminate with one business day notice.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.